NCT03595709View on ClinicalTrials.gov

Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

March 6, 2019

Study Completion Date

July 16, 2019

Conditions
HIV Infections
Interventions
DRUG

3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)

All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.

Trial Locations (2)

82445

E-Da Hospital, Kaohsiung City

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Yu-Jay Corp.

INDUSTRY

NCT03595709 - Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan | Biotech Hunter | Biotech Hunter